Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 1/20 | 0.57 |
| ▸ | CCND3 | P30281 | 1/20 | 0.57 |
| ▸ | CDK9 | P50750 | 1/20 | 0.57 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.56 |
| ▸ | JAK3 | P52333 | 6/20 | 0.51 |
| ▸ | JAK1 | P23458 | 4/20 | 0.51 |
| ▸ | JAK2 | O60674 | 3/20 | 0.51 |
| ▸ | TTK | P33981 | 3/20 | 0.51 |
| ▸ | TYK2 | P29597 | 2/20 | 0.51 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.51 |
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2519243 | 0.94 | CCNK (0.56) | CCNKCCND3CDK9CDK6NTRK1 | |
| SCHEMBL2515604 | 0.92 | JAK3 (0.53) | CCNKCCND3CDK9CDK6NTRK1 | |
| SCHEMBL2518058 | 0.92 | NTRK1 (0.63) | CCNKCCND3CDK9CDK6NTRK1 | |
| SCHEMBL2519106 | 0.91 | STK17A (0.52) | CCNKCCND3CDK9CDK6NTRK1 | |
| SCHEMBL13283861 | 0.91 | CCNK (0.58) | CCNKCCND3CDK9CDK6NTRK1 | |
| SCHEMBL2514435 | 0.91 | CCNK (0.64) | CCNKCCND3CDK9CDK6NTRK1 | |
| SCHEMBL2516086 | 0.87 | STK17A (0.52) | CCNKCCND3CDK9CDK6NTRK1 | |
| SCHEMBL2514431 | 0.86 | JAK3 (0.53) | CCNKCCND3CDK9CDK6NTRK1 | |
| SCHEMBL28936714 | 0.86 | NTRK1 (0.74) | NTRK1NTRK3NTRK2 | |
| SCHEMBL2516090 | 0.86 | STK17A (0.52) | CCNKCCND3CDK9CDK6NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765727-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765727-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765727-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085597-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CCNK 468/4885CCND3 2049/4885CDK9 201/4885 |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CCNK 468/4885CCND3 2049/4885CDK9 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.